Curtis Hanson, M.D., Elected as ACLA Chair - Insights
At the recent American Clinical Laboratory Association (ACLA) annual meeting, Curt Hanson, M.D., Chief Medical Officer at Mayo Medical Laboratories, was elected as Chair of the ACLA Board.
Mayo Clinic Laboratory and pathology research roundup: March 7 - Insights
This week's Research Roundup features: Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor.
Mayo Clinic Laboratory and pathology research roundup: December 8 - Insights
This week’s research roundup features: The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids.
Autoimmune GI Dysmotility - Mayo Clinic Laboratories
Identifying GI dysmotility as autoimmune-mediated is extremely important because patients treated with immunotherapy can see a dramatic improvement, going from persistent nausea, vomiting, and weight loss to feeling normal within a few...
Check out Mayo Clinic Laboratories’ biochemical and molecular testing options to diagnose creatine deficiency disorders.
Answers to the most commonly asked questions on shipping supplies and requirements, turn-around-times, and billing, among others.
Mayo Clinic Laboratories urologic pathology section provides consultations on kidney, bladder, prostate, testicular, and penile cases.
Plasma Cell Proliferative Disorder [Test in Focus] - Insights
Linda Baughn Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be...
Novel Laboratory Tests Transform Lupus Management: Bill Morice, M.D., Ph.D. - Insights
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa...
Sarcoma NGS Testing - Mayo Clinic Laboratories
n order to aid in the diagnosis for a wide range of tumors, our sarcoma NGS panel includes fusions in 138 individual genes.